Journal of Clinical Psychiatry E-Lert


Subscribe | Current Issue | Ahead of Print | Information for Authors

Table 2. Information to Consider in Selecting the Most Appropriate Antipsychotic Agent for the Specific Patient (1:01)


How to Interpret Findings Concerning Newly Approved Antipsychotic Agents: Clinical Implications of the Lurasidone PEARL 2 Study

Christoph U. Correll, MD (Chair), et al

Read this InfoPack to review a compilation of a detailed panel discussion on the results of the Program to Evaluate the Antipsychotic Response to Lurasidone (PEARL 2) study, a well-designed registration study that included an active control. The goal here is to help you better understand how to translate data from pivotal antipsychotic trials into useful information for managing specific patients in general clinical settings.

Support was provided by Sunovion Pharmaceuticals, Inc.

For more articles, visit the Journal at If you are having trouble reading this E-Lert, see

To receive E-Lerts from both The Journal of Clinical Psychiatry and The Primary Care Companion, update your profile.

Like us on Facebook
Follow us on Twitter
You are receiving this update as a benefit of your membership.
To ensure delivery of these messages add to your address book. If you would not like to receive further E-Lerts, go to and click the "Unsubscribe from E-Lerts" link. If you are having trouble unsubscribing, contact the web administrator for assistance.
If you are having trouble with your membership, contact our circulation department. Direct any other questions or comments to the web administrator.
Please do not reply directly to this e-mail.
If you cannot read this go to
Physicians Postgraduate Press, Inc. | 850 Ridge Lake Boulevard, Suite 300 | Memphis, TN 38120
© Copyright 2012, Physicians Postgraduate Press, Inc. All rights reserved.